Loading
NG-348 is an experimental cancer-killing virus from Akamis Bio, tested in a completed phase 1 study for advanced epithelial tumours.
NG-348 is an oncolytic adenovirus (T-SIGn), given into a vein, carrying a transgene from Akamis Bio. A tumour-selective adenovirus that makes infected tumour cells display CD80 and an anti-CD3 antibody fragment on their surface, so that T cells engage them directly. The company says a phase 1 study of NG-348 alone in metastatic or advanced epithelial tumours was completed and presented at SITC 2026, and its pipeline lists metastatic colorectal cancer as the intended use. No ClinicalTrials.gov record was found under NG-348 or NG348. Whether it works in people has not been established.
A tumour-selective adenovirus that makes infected tumour cells display CD80 and an anti-CD3 antibody fragment on their surface, so that T cells engage them directly. Connects to CD80 (B7-1) and CD3.
1.NG-348 slips into a pocket on CD80 (B7-1).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NG-348" OR ABSTRACT:"NG-348" OR TITLE:"NG348" OR ABSTRACT:"NG348") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NG-348, not a curated reading list.
Shares Akamis Bio and the tag pipeline.
Shares Akamis Bio and the tag pipeline.
Shares Akamis Bio and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/